Karen R. Jacobson, MD, MPH
Associate Professor
Boston University School of Medicine
Dept of Medicine
Infectious Diseases

MD, Johns Hopkins University School of Medicine
MPH, Harvard School of Public Health

Dr. Karen Jacobson is an Associate Professor of Medicine in the Section of Infectious Diseases, Boston University School of Medicine, with a secondary appointment in the Department of Epidemiology, Boston University School of Public Health. Dr. Jacobson’s research focuses on the epidemiology of tuberculosis, including identification of biological and social determinants of and risk factors for tuberculosis infection and disease (including drug resistant tuberculosis) and approaches for improving tuberculosis outcomes in resource-limited settings. Dr. Jacobson is the Medical Director of the Boston Medical Center Tuberculosis Clinic and has established a highly productive collaboration with researchers in Cape Town, South Africa. Her work has particular emphasis in understanding how substance use impacts on tuberculosis transmission and response to therapy.

Assistant Professor
Boston University School of Public Health

Boston University
Evans Center for Interdisciplinary Biomedical Research

Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL)
08/01/2019 - 07/31/2024 (PI)

Providence/Boston Center for AIDS Research(CFAR): HIV-TB SWG
07/01/2018 - 06/30/2023 (PI)
Miriam Hospital NIH-NIAID

Biomarkers and Mechanisms of Paucibacillary and Latent Tuberculosis
11/01/2018 - 07/31/2021 (PI)
Rutgers The State University of New Jersey NIH-NIAID

The impact of alcohol consumption on TB treatment outcomes
04/08/2016 - 03/31/2021 (PI)

URBAN ARCH (3/5) Uganda Cohort- TB prevention therapy for HIV-infected alcohol drinkers in Uganda…
09/22/2016 - 08/31/2020 (PI)
The Regents of the University of California NIH-NIAAA

ASTMH Fellowship in Tropical Infectious Diseases
02/01/2013 - 11/30/2018 (PI)
American Society of Tropical Medicine and Hygiene

Phase 2 Pharmacodynamic Study of Hidh-dose Levofloxacin in MDR-TB Treatment
01/01/2015 - 07/31/2018 (PI)
Trustees of Boston University NIH-NIAID

Lifespan/Tufts/Brown Center for AIDS Research(CFAR): SWG1
07/01/2017 - 06/30/2018 (PI)
Miriam Hospital NIH-NIAID

Geospatial clustering and molecular and social epidemiology of drug resistant TB
08/01/2013 - 12/31/2016 (PI)


Yr Title Project-Sub Proj Pubs
2020 Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL) 5R01AI147316-02
2020 The impact of alcohol consumption on TB treatment outcomes 5R01AI119037-05 3
2020 The impact of alcohol consumption on TB treatment outcomes 5R01AI119037-05 3
2020 SWG1: HIV/TB Scientific Working Group 5P30AI042853-22-7401 905
2019 Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL) 1R01AI147316-01
2019 The impact of alcohol consumption on TB treatment outcomes 5R01AI119037-04 3
2019 SWG1: HIV/TB Scientific Working Group 5P30AI042853-21-7401 905
2018 The impact of alcohol consumption on TB treatment outcomes 5R01AI119037-03 3
2018 SWG1: HIV/TB Scientific Working Group 2P30AI042853-20A1-7401 905
2017 The impact of alcohol consumption on TB treatment outcomes 5R01AI119037-02 3
Showing 10 of 17 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Kan CK, Ragan EJ, Sarkar S, Knudsen S, Forsyth M, Muthuraj M, Vinod K, Jenkins HE, Horsburgh CR, Salgame P, Roy G, Ellner JJ, Jacobson KR, Sahu S, Hochberg NS. Alcohol use and tuberculosis clinical presentation at the time of diagnosis in Puducherry and Tamil Nadu, India. PLoS One. 2020; 15(12):e0240595.View Related Profiles. PMID: 33332367
  2. He X, Eddy JJ, Jacobson KR, Henderson AJ, Agosto LM. Enhanced Human Immunodeficiency Virus-1 Replication in CD4+ T Cells Derived From Individuals With Latent Mycobacterium tuberculosis Infection. J Infect Dis. 2020 Oct 01; 222(9):1550-1560.View Related Profiles. PMID: 32417884
  3. Eddy JJ, Gadani KM, Tibbs A, Bernardo J, Cochran J, White LF, Horsburgh CR, Jacobson KR. Increasing Drug Resistance Among Persons With Tuberculosis in Massachusetts, 2009-2018. Open Forum Infect Dis. 2020 Aug; 7(8):ofaa300.View Related Profiles. PMID: 32855987
  4. Muyindike WR, Fatch R, Cheng DM, Emenyonu NI, Ngabirano C, Adong J, Linas BP, Jacobson KR, Hahn JA. Tuberculin skin test positivity among HIV-infected alcohol drinkers on antiretrovirals in south-western Uganda. PLoS One. 2020; 15(7):e0235261.View Related Profiles. PMID: 32614873
  5. Bouton TC, Jacobson KR. Symptom screens are not sufficient: the fight against tuberculosis needs better weapons. Clin Infect Dis. 2020 Apr 16.View Related Profiles. PMID: 32296819
  6. Ragan EJ, Kleinman MB, Sweigart B, Gnatienko N, Parry CD, Horsburgh CR, LaValley MP, Myers B, Jacobson KR. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2020 01 01; 24(1):73-82.View Related Profiles. PMID: 32005309
  7. Bouton TC, de Vos M, Ragan EJ, White LF, Van Zyl L, Theron D, Horsburgh CR, Warren RM, Jacobson KR. Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis. PLoS One. 2019; 14(10):e0223308.View Related Profiles. PMID: 31622366
  8. Bulabula ANH, Nelson JA, Musafiri EM, Machekano R, Sam-Agudu NA, Diacon AH, Shah M, Creswell J, Theron G, Warren RM, Jacobson KR, Chirambiza JP, Kalumuna D, Bisimwa BC, Katoto PDMC, Kaswa MK, Birembano FM, Kitete L, Grobusch MP, Kashongwe ZM, Nachega JB. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study. Clin Infect Dis. 2019 09 27; 69(8):1278-1287. PMID: 30759187
  9. van der Heijden YF, Hughes J, Dowdy DW, Streicher E, Chihota V, Jacobson KR, Warren R, Theron G. Overcoming limitations of tuberculosis information systems: researcher and clinician perspectives. Public Health Action. 2019 Sep 21; 9(3):120-127. PMID: 31803584
  10. Berhanu RH, Schnippel K, Kularatne R, Firnhaber C, Jacobson KR, Horsburgh CR, Lippincott CK. Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay. Int J Tuberc Lung Dis. 2019 03 01; 23(3):358-362.View Related Profiles. PMID: 30940300
Showing 10 of 35 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 35 publications over 12 distinct years, with a maximum of 8 publications in 2018

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

drug resistant tuberculosis
global health
spatial mapping

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

771 Albany St
Boston MA 02118
Google Map

Jacobson's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department